Accuray (ARAY) to Release Earnings on Wednesday

Accuray (NASDAQ:ARAY - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, January 29th. Analysts expect Accuray to post earnings of ($0.02) per share and revenue of $110,360.00 billion for the quarter. Accuray has set its FY 2025 guidance at EPS.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The company had revenue of $101.55 million during the quarter, compared to analyst estimates of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same quarter last year, the company earned ($0.03) earnings per share. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Price Performance

NASDAQ ARAY traded up $0.04 during trading on Wednesday, reaching $2.28. The company's stock had a trading volume of 550,658 shares, compared to its average volume of 699,158. The stock has a market capitalization of $229.30 million, a PE ratio of -13.41 and a beta of 1.47. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. The firm has a fifty day moving average of $2.01 and a 200 day moving average of $1.94. Accuray has a one year low of $1.40 and a one year high of $2.99.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Accuray from a "buy" rating to a "hold" rating in a research note on Friday, November 15th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.